Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Evidence that neutrophils do not promote Echis carinatus venom-induced tissue destruction.

Stackowicz J, Balbino B, Todorova B, Godon O, Iannascoli B, Jönsson F, Bruhns P, Reber LL.

Nat Commun. 2018 Jun 13;9(1):2304. doi: 10.1038/s41467-018-04688-6. No abstract available.

2.

Platelets expressing IgG receptor FcγRIIA/CD32A determine the severity of experimental anaphylaxis.

Beutier H, Hechler B, Godon O, Wang Y, Gillis CM, de Chaisemartin L, Gouel-Chéron A, Magnenat S, Macdonald LE, Murphy AJ; NASA study group, Chollet-Martin S, Longrois D, Gachet C, Bruhns P, Jönsson F.

Sci Immunol. 2018 Apr 13;3(22). pii: eaan5997. doi: 10.1126/sciimmunol.aan5997.

PMID:
29654057
3.

Innate Immune Basis for Rift Valley Fever Susceptibility in Mouse Models.

Lathan R, Simon-Chazottes D, Jouvion G, Godon O, Malissen M, Flamand M, Bruhns P, Panthier JJ.

Sci Rep. 2017 Aug 2;7(1):7096. doi: 10.1038/s41598-017-07543-8.

4.

IgG subclasses determine pathways of anaphylaxis in mice.

Beutier H, Gillis CM, Iannascoli B, Godon O, England P, Sibilano R, Reber LL, Galli SJ, Cragg MS, Van Rooijen N, Mancardi DA, Bruhns P, Jönsson F.

J Allergy Clin Immunol. 2017 Jan;139(1):269-280.e7. doi: 10.1016/j.jaci.2016.03.028. Epub 2016 Apr 26.

5.

Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.

Godon O, Evlachev A, Bourgine M, Meritet JF, Martin P, Inchauspe G, Michel ML.

Vaccine. 2015 Aug 26;33(36):4548-53. doi: 10.1016/j.vaccine.2015.07.020. Epub 2015 Jul 23.

PMID:
26209840
6.

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.

Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, Geist M, Brandely R, Findeli A, Boukhebza H, Menguy T, Silvestre N, Michel ML, Inchauspé G.

Gut. 2015 Dec;64(12):1961-71. doi: 10.1136/gutjnl-2014-308041. Epub 2014 Nov 26.

7.

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.

Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, Godon O, Meritet JF, Saïdi Y, Michel ML, Scott-Algara D, Aboulker JP, Pol S; ANRS HB02 study group.

Gut. 2015 Jan;64(1):139-47. doi: 10.1136/gutjnl-2013-305707. Epub 2014 Feb 20.

PMID:
24555998
8.

Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues.

Godon O, Fontaine H, Kahi S, Meritet JF, Scott-Algara D, Pol S, Michel ML, Bourgine M; ANRS HB02 study group.

Mol Ther. 2014 Mar;22(3):675-684. doi: 10.1038/mt.2013.274. Epub 2013 Dec 5.

9.

Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules.

Dion S, Bourgine M, Godon O, Levillayer F, Michel ML.

J Virol. 2013 May;87(10):5554-63. doi: 10.1128/JVI.03134-12. Epub 2013 Mar 6.

10.

T-cell responses to hepatitis B splice-generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP-FIBRO.

Bayard F, Godon O, Nalpas B, Costentin C, Zhu R, Soussan P, Vallet-Pichard A, Fontaine H, Mallet V, Pol S, Michel ML.

J Viral Hepat. 2012 Dec;19(12):872-80. doi: 10.1111/j.1365-2893.2012.01611.x. Epub 2012 Apr 19.

PMID:
23121366
11.

Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model.

Bourgine M, Dion S, Godon O, Guillen G, Michel ML, Aguilar JC.

Virology. 2012 Aug 15;430(1):10-9. doi: 10.1016/j.virol.2012.04.007. Epub 2012 May 15.

Supplemental Content

Support Center